The move makes Moderna’s vaccine, called Spikevax, the first COVID shot for kids in the U.S. to be fully approved, rather ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S.

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...

The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...

Brookline Capital Markets analyst Leah R. Cann reiterated a Buy rating on Moderna today and set a price target of $198.00. The company’s shares closed today at $34.28. Elevate Y ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Moderna today and set a price target of $31.00. The company’s shares opened today at $33.30. Elevate Your Invest ...